Wednesday, February 10, 2010, 1:34am EST - Canadian Markets open in 7 hours and 56 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

ADDEX PHARMAC N (ADXN.SW)

 On Feb 9: 11.65 CHF  Down 0.10 (0.85%)  
MORE ON ADXN.SW
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
ADDEX PHARMAC N (EBS:ADXN.SW) Delayed quote dataEdit
Last Trade: 11.65 CHF
Trade Time: Feb 9
Change: Down 0.10 (0.85%)
Prev Close: 11.85
Open: 11.85
Bid: 11.70
Ask: 12.00
1y Target Est: N/A
Day's Range: 11.50 - 12.05
52wk Range: 10.05 - 41.95
Volume: 7,353
Avg Vol (3m): 35,014.3
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A%)
ADDEX PHARMAC N (ADXN.SW)
1d  5d  3m  6m  1y  2y  5y 
 Add ADXN.SW to Portfolio   Download Data

HEADLINES
• Development of ADX10059 Ended for Long-Term Use
Marketwire (Tue, Dec 15)
• Addex Ends Migraine Prevention Study
Marketwire (Mon, Dec 14)
• Addex Extends Parkinson's Disease Collaboration with Merck & Co., Inc.
Marketwire (Wed, Dec 2)
• Addex ADX48621 Positive Primate Parkinson's Data
Marketwire (Tue, Nov 24)
• Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial
Marketwire (Mon, Nov 16)
• Addex Presents ADX10059 PD-LID Data at GPCR Drug Discovery Conference
Marketwire (Tue, Nov 3)
• Addex Completes Enrollment of First Mid-Stage Clinical GERD Trial
Marketwire (Mon, Sep 28)
• Laurent Massuyeau, Head of Business Development, Resigns
Marketwire (Thu, Sep 17)
• Addex' ADX10059 has potential for Parkinson's disease levodopa induced dyskinesia (PD-LID)
Marketwire (Mon, Sep 14)
• Addex Pharmaceuticals Reports First Half 2009 Financial Results
Marketwire (Tue, Jul 28)
More Headlines for ADXN.SW...
BUSINESS SUMMARY
No business summary available for ADXN.SW.


Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices